Vol.260 | Weekly Highlights of IVD and Precision Medicine Industry and Investment

Oct 11, 2024 14:30 CST Updated 14:30

Illumina

Diagnostic Product Developer

Chemiluminescence, selected by the Ministry of Industry and Information Technology and the National Health Commission

Advanced Medical Equipment Promotion and Application Project!

Recently, the General Office of the Ministry of Industry and Information Technology and the General Office of the National Health Commission issued the "Notice of the General Office of the Ministry of Industry and Information Technology and the General Office of the National Health Commission on Carrying Out the Application Project Declaration Work for High-End Medical Equipment Promotion in 2024" (hereinafter referred to as the "Notice").

The Notice points out that, for typical application scenarios, a group of high-end medical equipment projects with technological innovation and clinical application levels at the forefront in China should be selected. These projects should play a strong leading and promoting role in the collaborative innovation of high-end medical equipment engineering and medicine, pilot testing, clinical research, iterative upgrading, and promotion and application. This year, the focus will be on promoting the application of high-end medical equipment in five directions: diagnosis and testing, treatment, monitoring and life support, elderly care and rehabilitation, and artificial intelligence-assisted diagnosis and treatment.These include MRI, CT, PET/CT, DSA, color Doppler ultrasound, fully automatic chemiluminescence immunoassay analyzers, endoscopic surgical robots, orthopedic navigation robots, neurosurgical navigation robots, ECMO, cochlear implants, and more.

Heavyweight! The Nobel Prize in Physiology or Medicine Announced

At approximately 5:30 PM Beijing time on October 7, the 2024 Nobel Prize in Physiology or Medicine was announced!The achievements of the Nobel Prize in Physiology or Medicine have profoundly impacted human health. It is not only the highest honor in the scientific community but also the most widely followed award over the years.American scientists Victor Ambros and Gary Ruvkun won the award,In recognition of their"DiscoverymicroRNAAnd its role in post-transcriptional gene regulation".

Illumina Leadership Changes Again

On October 3, according to Illumina, Charles Dadswell, General Counsel of Illumina, is about to step down and will continue to serve as a consultant until the end of March 2025. The company has appointed Scott Davies as interim General Counsel and Secretary and is actively seeking a new successor. It is reported that Charles Dadswell joined the company in 2013 as General Counsel. Prior to this, he served as legal counsel in the biotechnology field and has had a distinguished career. Recently, he was responsible for overseeing the company’s successful challenge to the European Commission's jurisdiction over Illumina's acquisition of GRAIL at the European Court of Justice.

Beckman, New President Takes Office!

Danaher Subsidiary Beckman Coulter Life Sciences Appoints Joe Fox as President, Effective Immediately.

Fox once served as the president of Sciex, a subsidiary of Danaher, and held several leadership positions at the company before becoming president, including Senior Vice President of Global Sales and Service.He has also worked at Bruker, a life science instruments company, andShimadzuHold technical and commercial positions.

Abbott Diagnostics, A New Milestone of Made in China!

October 9, 2024, Hangzhou — Abbott, a global leading healthcare company, announced the official launch of its domestically produced Alinity i immunoassay module and GLP automated流水line, marking a new chapter in the localized production of these two intelligent solutions at Abbott’s diagnostics facility in Hangzhou. In the future, innovative diagnostic resources made in China will reach more regions, helping to foster new productivity in the medical field.

On the first trading day after the holiday, IVD stocks surged collectively again!

The First Day Back to Work After National Day, the IVD Industry Surged Collectively Once Again!On October 8, the rally in China's A-share market continued, at 9:00 AM:On the first trading day after the holiday, China's three major stock indices opened significantly higher, with the Shanghai Composite Index up 10.13%, the Shenzhen Component Index up 12.67%, and the ChiNext Index up 18.44%.The BeiZheng 50 Index opened 26.67% higher.

MGI Tech, NanoMicro, Impec Medical, Novozymes and other companies showed significant increases, with a total of 19 IVD enterprises experiencing gains exceeding 10%.As of press time, Mindray Medical's stock price was 329.08 yuan per share, with a total market value of 399 billion yuan.

Hubei Xinzongke Completes Tens of Millions in Series B Financing,

Accelerate the Innovation and Promotion of Flow Fluorescence Technology Applications

Recently, Hubei Xinzongke Viral Disease Engineering Technology Co., Ltd. ("Xinzongke" for short) announced the completion of a multi-million RMB Series B financing round. This round was led by Wuhan Boxin Venture Capital Partnership (Limited Partnership) ("Boxin Ventures" for short), a life science tools fund jointly initiated by Luxin Venture Capital, Epizyme Biotech, and Wuhan Innovation Institute. Shenzhen Kelaisi Technology Co., Ltd. ("Kelaisi" for short) also participated in the investment. This round of financing will further accelerate the innovative application and commercial promotion of flow fluorescence technology, providing more customers with high-performance, cost-effective one-stop flow fluorescence product solutions and services.

2 billion US dollars,

CSPC Pharmaceutical Group Reaches Exclusive Licensing Agreement with AstraZeneca

On October 7, CSPC Pharmaceutical Group announced that it had entered into an exclusive licensing agreement with AstraZeneca for the global development, manufacturing, and commercialization of a preclinical innovative small molecule lipoprotein(a) (Lp(a)) inhibitor from the group’s portfolio, as well as any pharmaceuticals or biologics containing or composed of this compound developed subsequently.

Chinese Mass Spectrometry Companies Complete Tens of Millions in Financing!

Recently, Tianjin Zhipu Instrument Co., Ltd., which focuses on the niche field of mass spectrometry instruments, has completed a Pre-A round of financing worth tens of millions of yuan. This round of financing was led by Beiyang Haitang Fund, with participation from Haihe Industrial Fund, iFlytek Ventures, Jiuan Medical, and Binhai Industrial Fund.The funds from this round of financing will be mainly used for the serialization of high-end mass spectrometry instruments, the independent research and development of fully automated intelligent medical mass spectrometry platforms, the integration of mass spectrometry and artificial intelligence technology, and the market expansion of already listed products.

Illumina Leads the Investment,

Dayuan Chenguang Completes Tens of Millions of RMB in Pre-A Round Financing

Shenzhen Dayuan Chenguang Technology Co., Ltd. announced the completion of a Pre-A round of financing worth tens of millions of RMB. This round was led by existing shareholder Yahui Long, with Yanghe Investment following up. The funds raised will be used for global market development, new product research and development, and capacity enhancement, providing strong support for Dayuan Chenguang to improve its product line and promote its internationalization strategy.

12.6 Billion! Roche Fully Acquires Respiratory Multiplex Nucleic Acid Testing

Roche will fully acquire GenMark in an all-cash transaction at a price of $24.05 per share. This equates to a total transaction value of approximately $1.8 billion on a fully diluted basis. Upon completion of the acquisition, GenMark’s core operations will continue at its existing location in Carlsbad, California, USA. GenMark’s portfolio of syndromic testing products will complement Roche’s current molecular diagnostics offerings, while Roche’s global network will expand the reach of GenMark’s products.